GLP.exe - a cheap and safe treatment for diabetes mellitus type 2
Several treatment options for type 2 diabetes mellitus
have been developed in recent years.
Hence, the diagnosis of type 2 diabetes mellitus is no longer a death sentence.
Current Drugs
...are expensive, require fine tuning and daily shots.
Moreover, they have severe side-effects, causing patients to skip doses.
“Many patients don’t want to use insulin. They don’t want
to do finger sticks and they’re afraid of hypoglycemia.”
“To fight the global diabetes pandemic, we would ideally have an accessible cost-effective
easily-compliant intervention that has high clinical efficacy and that is free of adverse side effects.”
Prof. Harold Lebovitz, State University of New York Health Science Center, Brooklyn, New York
There's a solution!
Our therapeutic agent is a probiotic secreting incretin
mimetics placed in the patients intestine by oral administration of capsules. GLP-1 and Exendin-4, our
main actors, cause an increase in insulin secretion, if the cell has already taken up sugar.
This enables an easier therapy where a regular intake of
medicals are not required.
Improved cell penetrating peptides with the use of
artificial intelligence allow for an efficient and safe transport of our effectors into the cells.
is our highest priority!
Therefore, we developed a novel, Cas3 based kill-switch
mechanism. The flexible system uses three regulators inspired by the human intestines: temperature,
availability of fatty acids in form of Acyl CoA and N-Acetyl-Glucosamin.
If the conditions of our regulatory system are no longer met, Cas3 will be degrading all genetic
information.
An in depth E.coli Nissle characterization.
Despite the fact that E. Coli Nissle is an alreasdy
approved probiotic, it's surprisingly badly characterized.
Hence, we provide the first metabolic model of E. coli Nissle and optimize it's growth for various
growth media. Furthermore, we predicted the interaction and competition of E. coli Nissle with common
competitors for various fluxes.
Finally, we carried out a series of RNA-Seq experiments to assess the adaptions and reactions of E. coli
Nissle to aerob, as well as anaerob occuring stress factors.
Our work lays the foundation of an innovative, unprecedented approach to treat diabetes mellitus type 2.
